Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Early discharge program cost savings for patients with newly diagnosed acute myeloid leukemia after intensive induction chemotherapy

View Full Paper
Ask AI
Bookmark
Share

Authors

KCKarthik ChetlapalliSBSabrina L. BrowningLMLourdes M. Mendez

Discussion

Loading...

Member takes

Overview

Analysis shows cost benefits of early discharge in patients with AML after intensive chemotherapy, indicating it reduces hospital expenses.

Key Points

  • Early discharge from chemotherapy leads to significant cost savings for hospitals with acute myeloid leukemia patients.
  • Median total costs for early discharge were $19,473 compared to $22,267 for traditional discharges.
  • Assessment of costs included outpatient appointments, transfusions, and intravenous antimicrobial therapy days.
  • This approach emphasizes resource efficiency, potentially freeing up hospital beds for other patients needing care.

Cite This Study

Chetlapalli et al. (2025) studied this question.

synapsesocial.com/papers/69362f6c4fa91c937236df98https://doi.org/10.1182/blood-2025-6208
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Outpatient cytarabine consolidation in acute myeloid leukemia safely reduces hospitalization time and treatment costs2025 · 3 citations
  2. 2Impact of hospital admissions through the emergency department versus direct admissions for patients with hematologic malignancies: A single site analysis2025
  3. 3National analysis of real-world racial and ethnic disparities in mortality, complications, and healthcare costs among adults hospitalized with newly diagnosed Acute Myeloid Leukemia2025
  4. 4Determinants of early mortality following induction chemotherapy in Acute Myeloid Leukemia: Experience from a comprehensive cancer center in Latin America2025
  5. 5AML Care at Home: An Evidence-Based Toolkit to Personalize the Care Setting for Recovery From Pediatric AML Chemotherapy2025